eastern cooperative eastern cooperative oncology group oncology group ACRIN Annual ACRIN Annual Meeting Meeting OVERVIEW OF ECOG OVERVIEW OF ECOG Robert L. Comis, M.D. Robert L. Comis, M.D. Chair Chair Eastern Cooperative Oncology Eastern Cooperative Oncology Group Group September 22, 2011 September 22, 2011
19
Embed
Eastern cooperative oncology group ACRIN Annual Meeting OVERVIEW OF ECOG Robert L. Comis, M.D. Chair Eastern Cooperative Oncology Group September 22, 2011.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
eastern cooperativeeastern cooperative oncology grouponcology group
The Eastern Cooperative Oncology Group (ECOG) The Eastern Cooperative Oncology Group (ECOG) is a multidisciplinary organization devoted to the is a multidisciplinary organization devoted to the
prevention, treatment and study of neoplastic prevention, treatment and study of neoplastic disease that will eventually lead to the control and disease that will eventually lead to the control and
cure of cancer.cure of cancer.
1
eastern cooperative oncology groupeastern cooperative oncology group
Colorado Cancer Research Program CCOPColorado Cancer Research Program CCOP Cook County MBCCOP*Cook County MBCCOP* Evanston Hospital CCOPEvanston Hospital CCOP Kalamazoo CCOPKalamazoo CCOP Main Line Health CCOPMain Line Health CCOP Marshfield Clinic CCOPMarshfield Clinic CCOP Medical College of Georgia MBCCOP*Medical College of Georgia MBCCOP* Meharry Medical College MBCCOP*Meharry Medical College MBCCOP* Metro-Minnesota CCOPMetro-Minnesota CCOP Ochsner CCOPOchsner CCOP Oklahoma CCOPOklahoma CCOP San Juan MBCCOP*San Juan MBCCOP* SUNY Downstate MBCCOP*SUNY Downstate MBCCOP* St Vincent Hospital Regional Center CCOPSt Vincent Hospital Regional Center CCOP
5
*Minority Based CCOP
eastern cooperative oncology groupeastern cooperative oncology group
Administrative and Scientific Administrative and Scientific Organizational StructureOrganizational Structure
Administrative and Scientific Administrative and Scientific Organizational StructureOrganizational Structure
Administrative Committees
- Audit
- CRA
- Data Monitoring
- Executive Review
- Nominating
- Oncology Nursing
- Patient Representative
- Pharmacy
- Radiation Oncology
- Surgery
Scientific Committees
Disease Committees Other Scientific Committees
- Breast - Laboratory Science
- Gastrointestinal and Pathology
- Genitourinary - Developmental Therapeutics
- Head and Neck - Pathology Coordinating
- Leukemia Office/Reference Laboratory
- Lymphoma - Central Immunologic
- Melanoma Monitoring Laboratory
- Myeloma - Leukemia Laboratory
- Thoracic - Cytogenetics
DCP Funded Committees:
- Patient Outcomes, Survivorship and Underserved
- Prevention
- Symptom Management
6
eastern cooperative oncology groupeastern cooperative oncology group
AccrualAccrualRegistrations to Therapeutic StudiesRegistrations to Therapeutic Studies
AccrualAccrualRegistrations to Therapeutic StudiesRegistrations to Therapeutic Studies
(Projected)(Average)
0100020003000400050006000700080009000
10000
Grant Year
Reg
istr
ati
on
s
85746975
44655220
3450
9073
5737
3157
5042
7
eastern cooperative oncology groupeastern cooperative oncology group
ECOG patients accrued to other intergroup studies 1,714
8
eastern cooperative oncology groupeastern cooperative oncology group
Major AccomplishmentsMajor AccomplishmentsMajor AccomplishmentsMajor Accomplishments
Six studies led to new standard of care and FDA indicationsSix studies led to new standard of care and FDA indications Bevacizumab in metastatic colon (E3200), lung (E4599), Bevacizumab in metastatic colon (E3200), lung (E4599),
breast (E2100)breast (E2100) Rituximab in indolent (E1496) and aggressive Rituximab in indolent (E1496) and aggressive
lymphoma (E4494)lymphoma (E4494) Thalidomide in multiple myeloma (E1A00)Thalidomide in multiple myeloma (E1A00)
Two phase III adjuvant trials:Two phase III adjuvant trials: E5103 – bevacizumab + chemotherapy in HER2-E5103 – bevacizumab + chemotherapy in HER2-
negative breast cancernegative breast cancer E1505 – bevacizumab + chemotherapy in stage IB – IIIA E1505 – bevacizumab + chemotherapy in stage IB – IIIA
NSCLCNSCLC
9
eastern cooperative oncology groupeastern cooperative oncology group
Major AccomplishmentsMajor AccomplishmentsMajor AccomplishmentsMajor Accomplishments
Head and Neck cancer: defined prognostic and Head and Neck cancer: defined prognostic and predictive roles of p53 mutations and HPV+predictive roles of p53 mutations and HPV+
AML: established superiority of high dose AML: established superiority of high dose daunorubicin inductiondaunorubicin induction
Adult ALL: defined new adverse cytogenetic Adult ALL: defined new adverse cytogenetic parametersparameters
Breast cancer: described VEGF SNPs related to Breast cancer: described VEGF SNPs related to response and toxicity; and potential new response and toxicity; and potential new therapeutic targets (eg, GRB-7)therapeutic targets (eg, GRB-7)
Multiple Myeloma: established superiority of low Multiple Myeloma: established superiority of low dose dexamethasone plus lenalidomide in dose dexamethasone plus lenalidomide in induction therapyinduction therapy
10
eastern cooperative oncology groupeastern cooperative oncology group
Publication Record (2004-2008)Publication Record (2004-2008)Publication Record (2004-2008)Publication Record (2004-2008)
JCOJCO 9393
BloodBlood 1818
NEJMNEJM 99
11
eastern cooperative oncology groupeastern cooperative oncology group
Laboratory Science and Pathology Laboratory Science and Pathology Committee (LSPC)Committee (LSPC)
Reviews, comments on and approves Reviews, comments on and approves all ECOG related grant studies prior all ECOG related grant studies prior to submissionto submission
22 R01 and R21 proposals were reviewed and 22 R01 and R21 proposals were reviewed and approved by LSPCapproved by LSPC
50% of RO1 and R21 submissions were funded 50% of RO1 and R21 submissions were funded by NIHby NIH
12
eastern cooperative oncology groupeastern cooperative oncology group
Leukemia Laboratory Committee and Leukemia Leukemia Laboratory Committee and Leukemia Translational Research LaboratoryTranslational Research Laboratory
Translational Science TeamTranslational Science Team
IT infrastructureIT infrastructure
1514
eastern cooperative oncology groupeastern cooperative oncology group
Major AccomplishmentsMajor AccomplishmentsMajor AccomplishmentsMajor Accomplishments
Established scientific infrastructure to perform Established scientific infrastructure to perform large-scale biomarker driven studieslarge-scale biomarker driven studies
Launched two large marker-driven phase III Launched two large marker-driven phase III studiesstudies
E5202 – stage II colon cancer (MSI; 18q LOH)E5202 – stage II colon cancer (MSI; 18q LOH)
TAILORx (PACCT-1) – node negative breast TAILORx (PACCT-1) – node negative breast cancer (Oncotype-DX)cancer (Oncotype-DX)
1615
eastern cooperative oncology groupeastern cooperative oncology group
eastern cooperative oncology groupeastern cooperative oncology group
General Themes for the FutureGeneral Themes for the FutureGeneral Themes for the FutureGeneral Themes for the Future
Study “targeted” therapies with the ultimate goal Study “targeted” therapies with the ultimate goal of developing new potentially curative strategiesof developing new potentially curative strategies
Define new predictive and prognostic factors Define new predictive and prognostic factors which lead to hypothesis driven clinical trialswhich lead to hypothesis driven clinical trials
Continue to develop both laboratory-based Continue to develop both laboratory-based and IT infrastructureand IT infrastructure
Build upon new data from existing pivotal studies Build upon new data from existing pivotal studies undergoing completion and analysisundergoing completion and analysis